Therapeutic Potential of Phages to Cure UTI

Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections – Case Report

Antimicrob Agents Chemother, 2023 Apr 18;67(4):e0003723.

https://doi.org/10.1128/aac.00037-23

Abstract

Recurrent urinary tract infections (rUTI) are common in kidney transplant recipients (KTR) and are associated with multidrug resistance and increased morbidity/mortality. Novel antibiotic alternatives to reduce UTI recurrence are critically needed. We describe a case of rUTI due to extended spectrum beta lactamase (ESBL) Klebsiella pneumoniae in a KTR that was treated successfully with 4 weeks of adjunctive intravenous bacteriophage therapy alone, without concomitant antibiotics, and with no recurrence in a year of follow-up.

Unknown's avatar

Published by Dr. Prasanth Manohar, Ph.D.,

Early career researcher in the field of Microbiology. Phage biologist, Author, Editor and Scientific writer. Expertise is in bacteriophage biology & genetics, Phage Therapy, ssRNA phages, Phage lysis systems, Single-cell analysis, protein antibiotics, and Antibiotic Resistance.